Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study

This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raffaele Parrozzani, Giulia Marchione, Alberto Fantin, Luisa Frizziero, Sabrina Salvadori, Daniel Nardo, Giulia Midena
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	retinopathy of prematurity inflammation platelets thrombocytopenia CRP glycemia Medicine R
Acceso en línea:	https://doaj.org/article/17098bfccc0c44f384639fa0a802e101
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17098bfccc0c44f384639fa0a802e101
record_format	dspace
spelling	oai:doaj.org-article:17098bfccc0c44f384639fa0a802e1012021-11-25T18:07:21ZThrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study10.3390/jpm111111202075-4426https://doaj.org/article/17098bfccc0c44f384639fa0a802e1012021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1120https://doaj.org/toc/2075-4426This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating treatment (group ROP1), ROP regressed without therapy (group ROP2) and no ROP (group no-ROP), divided in two phases for each group depending on gestational age. Blood parameters were weekly gathered and referred to postmenstrual age, ROP severity and phase. Platelet count mean values were statistically lower (<i>p</i> < 0.001) during both phases in ROP1 group (179 × 10<sup>9</sup>/L vs. 213 × 10<sup>9</sup>/L in phase 1 and 2, respectively) vs. other groups (ROP2: 286 × 10<sup>9</sup>/L vs. 293 × 10<sup>9</sup>/L; no ROP: 295 × 10<sup>9</sup>/L vs. 313 × 10<sup>9</sup>/L). Platelet count at birth <181 × 10<sup>9</sup> was statistically associated with Type 1 ROP development and evolution (sensibility = 76.47%, 95% confidence interval 60.0–87.6; specificity = 66.12%, 95% confidence interval 57.3–73.9). In ROP 1 group, a platelets count mean value “spike” (392.6 × 109/L) was documented at 36 weeks of corrected gestational age, preceding the need for treatment performed at a median of 38.1 ± 3.2 weeks. Early birth thrombocytopenia is confirmed as a biomarker of development and progression of ROP requiring treatment. The increase of platelets count at 35–37 weeks of corrected gestational age can be considered a possible clinical biomarker anticipating Type 1 ROP progression in preterm infants.Raffaele ParrozzaniGiulia MarchioneAlberto FantinLuisa FrizzieroSabrina SalvadoriDaniel NardoGiulia MidenaMDPI AGarticleretinopathy of prematurityinflammationplateletsthrombocytopeniaCRPglycemiaMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1120, p 1120 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	retinopathy of prematurity inflammation platelets thrombocytopenia CRP glycemia Medicine R
spellingShingle	retinopathy of prematurity inflammation platelets thrombocytopenia CRP glycemia Medicine R Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
description	This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating treatment (group ROP1), ROP regressed without therapy (group ROP2) and no ROP (group no-ROP), divided in two phases for each group depending on gestational age. Blood parameters were weekly gathered and referred to postmenstrual age, ROP severity and phase. Platelet count mean values were statistically lower (<i>p</i> < 0.001) during both phases in ROP1 group (179 × 10<sup>9</sup>/L vs. 213 × 10<sup>9</sup>/L in phase 1 and 2, respectively) vs. other groups (ROP2: 286 × 10<sup>9</sup>/L vs. 293 × 10<sup>9</sup>/L; no ROP: 295 × 10<sup>9</sup>/L vs. 313 × 10<sup>9</sup>/L). Platelet count at birth <181 × 10<sup>9</sup> was statistically associated with Type 1 ROP development and evolution (sensibility = 76.47%, 95% confidence interval 60.0–87.6; specificity = 66.12%, 95% confidence interval 57.3–73.9). In ROP 1 group, a platelets count mean value “spike” (392.6 × 109/L) was documented at 36 weeks of corrected gestational age, preceding the need for treatment performed at a median of 38.1 ± 3.2 weeks. Early birth thrombocytopenia is confirmed as a biomarker of development and progression of ROP requiring treatment. The increase of platelets count at 35–37 weeks of corrected gestational age can be considered a possible clinical biomarker anticipating Type 1 ROP progression in preterm infants.
format	article
author	Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena
author_facet	Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena
author_sort	Raffaele Parrozzani
title	Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
title_short	Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
title_full	Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
title_fullStr	Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
title_full_unstemmed	Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
title_sort	thrombocytopenia as type 1 rop biomarker: a longitudinal study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/17098bfccc0c44f384639fa0a802e101
work_keys_str_mv	AT raffaeleparrozzani thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT giuliamarchione thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT albertofantin thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT luisafrizziero thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT sabrinasalvadori thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT danielnardo thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT giuliamidena thrombocytopeniaastype1ropbiomarkeralongitudinalstudy
_version_	1718411603593920512

Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study

Ejemplares similares